:JWH-193

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 451605875

| IUPAC_name = (1-(2-Morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone

| image = JWH-193.svg

| width = 150

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA = Schedule II

| legal_DE = NpSG

| legal_UK = Class B

| legal_US = Schedule I

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 133438-58-1

| ATC_prefix =

| ATC_suffix =

| PubChem = 10250276

| UNII = WB1TIJ1IO9

| UNII_Ref = {{fdacite|correct|FDA}}

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID = 8425762

| C=26 | H=26 | N=2 | O=2

| smiles = c3cccc1c3c(ccc1C)C(=O)c5c2ccccc2n(c5)CCN4CCOCC4

| StdInChI = 1S/C26H26N2O2/c1-19-10-11-23(21-7-3-2-6-20(19)21)26(29)24-18-28(25-9-5-4-8-22(24)25)13-12-27-14-16-30-17-15-27/h2-11,18H,12-17H2,1H3

| StdInChIKey = ICKWPPYMDARCKJ-UHFFFAOYSA-N

}}

JWH-193 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB₁ receptor of 6 nM, binding around seven times more tightly than the parent compound JWH-200,{{cite journal | vauthors = Huffman JW, Padgett LW | title = Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes | journal = Current Medicinal Chemistry | volume = 12 | issue = 12 | pages = 1395–411 | date = 2005 | pmid = 15974991 | doi = 10.2174/0929867054020864 }} though with closer to twice the potency of JWH-200 in activity tests.

In the United States, all CB₁ receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-193 are Schedule I Controlled Substances.{{UnitedStatesCode2|21|812|Schedules of controlled substances}}